Who are Bupivacaine heavy and Morphine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levobupivacaine plus sufentanil epidural infusion, Hyperbaric bupivacaine+Morphine, Bupivacaine + Sufentanil epidural, Hyperbaric bupivacaine+Sufentanil, Levobupivacaine 0.07% + Sufentanil 0.3µg/ml, Levobupivacaine 0.1% + Sufentanil 0.2µg/ml.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bupivacaine-heavy-and-morphine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Bupivacaine heavy and Morphine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bupivacaine heavy and Morphine (Bupivacaine heavy and Morphine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic + opioid combination. Area: Anesthesiology / Pain Management.

marketed Local anesthetic + opioid combination Voltage-gated sodium channels (bupivacaine); mu-opioid receptor (morphine) Anesthesiology / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Bupivacaine heavy and Morphine (Bupivacaine heavy and Morphine) — Post Graduate Institute of Medical Education and Research, Chandigarh. Bupivacaine heavy (hyperbaric) provides local anesthesia via sodium channel blockade, while morphine provides opioid analgesia via mu-receptor agonism, used together for intrathecal spinal anesthesia and analgesia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bupivacaine heavy and Morphine TARGET	Bupivacaine heavy and Morphine	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu-opioid receptor (morphine)
Levobupivacaine plus sufentanil epidural infusion	Levobupivacaine plus sufentanil epidural infusion	University of Genova	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (levobupivacaine); mu-opioid receptor (sufentanil)
Hyperbaric bupivacaine+Morphine	Hyperbaric bupivacaine+Morphine	Fundación Pública Andaluza Progreso y Salud	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptors (morphine)
Bupivacaine + Sufentanil epidural	Bupivacaine + Sufentanil epidural	Charles University, Czech Republic	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (sufentanil)
Hyperbaric bupivacaine+Sufentanil	Hyperbaric bupivacaine+Sufentanil	Fundación Pública Andaluza Progreso y Salud	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu-opioid receptors (sufentanil)
Levobupivacaine 0.07% + Sufentanil 0.3µg/ml	Levobupivacaine 0.07% + Sufentanil 0.3µg/ml	Dr Madeleine Wilwerth	phase 3	Local anesthetic + opioid combination	Voltage-gated sodium channels (levobupivacaine); mu opioid receptor (sufentanil)
Levobupivacaine 0.1% + Sufentanil 0.2µg/ml	Levobupivacaine 0.1% + Sufentanil 0.2µg/ml	Dr Madeleine Wilwerth	phase 3	Local anesthetic + opioid combination	Voltage-gated sodium channels (levobupivacaine); mu opioid receptor (sufentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic + opioid combination class)

Dr Madeleine Wilwerth · 2 drugs in this class
Fundación Pública Andaluza Progreso y Salud · 2 drugs in this class
Charles University, Czech Republic · 1 drug in this class
Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
University of Genova · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bupivacaine heavy and Morphine — Competitive Intelligence Brief. https://druglandscape.com/ci/bupivacaine-heavy-and-morphine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab